Close
Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose

Press release: Uppsala, December 2, 2021. Dicot's latest animal study demonstrates effect of the drug candidate LIB-01 even at low dose and the 7-day duration of effect on erectile function was confirmed, which provides solid ground for coming clinical studies in humans.

As previously reported, Dicot is conducting animal studies in collaboration with the French contract laboratory Pelvipharm, where the drug candidate LIB-01's effect on erectile function is tested in both healthy rats and in animals in a disease model.

The latest results from studies conducted on healthy rats confirm previous results, the potency effect lasts for a longer period of time after the end of dosing. Tests were designed to evaluate whether lower doses of LIB-01 have an effect and results demonstrate effect even at one tenth of the previously tested dose. The results are important from safety aspects and also implies lower costs of goods of a future pharmaceutical product.

The tests were also designed to investigate the duration of LIB-01's effect on erectile function after administration. The erectile effect was measured 7 days after dosing, as in previous studies, but also after longer time periods, and was compared with rats in a control group receiving placebo. The results demonstrated effect both after 7 days and more. Dicot now plans to conduct further studies on doses and long-term effect to confirm duration and appropriate doses for the first human clinical studies.

"Demonstrated effect at 10 folded lower dose is important since it provides opportunities for a low dose treatment, reducing the risk of potential side effects. Long-term effect is one of the key factors in developing new class of drugs for treatment of erectile dysfunction" says Göran Beijer, CEO of Dicot.

"There is a clear medical need in patients who suffer from erectile dysfunction. We have now established, in several studies, that LIB-01 truly has an effect. The duration is more than seven days and its now also demonstrated that low dose has a good effect. I am therefore confident that Dicot's drug candidate is effective" comments Professor François Giuliano, founder of Pelvipharm.

For further information, please contact:

Göran Beijer CEO
Tel: +46 706 63 60 09
Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,250 shareholders. For more information, please visit www.dicot.se.

This information is information that Dicot AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 2 December 2021.